HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Colon Cancer.
Eli Lilly-backed Zephyr AI secures $111m for precision medicine tech – Pharmaceutical Technology
Share this article Zephyr AI’s current target areas are in oncology and cardiometabolic diseases. Image credit: Shutterstock/NicoElNino. The startup funding landscape for deep technology companies